New combo therapy targets hard-to-treat lymphomas in early trial
NCT ID NCT06139406
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 24 times
Summary
This early-stage study tests a new drug (JNJ-87801493) combined with immune-activating therapies for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goals are to check safety and find the best dose. About 70 participants will take part in two phases: first to find a safe dose, then to study that dose more closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, 3084, Australia
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Linear Clinical Research Ltd
Nedlands, 6009, Australia
-
Odense University Hospital
Odense, 5000, Denmark
-
Rigshospitalet
Copenhagen, DK-2100, Denmark
-
Scientia Clinical Research
Randwick, 2031, Australia
-
Sourasky (Ichilov) Medical Center
Tel Aviv, 6423906, Israel
-
The Alfred Hospital
Melbourne, 3004, Australia
Conditions
Explore the condition pages connected to this study.